In this study, ELISA was used to detect three traditional EBV-related biomarkers (EA-IgA, Rta-IgG and VCA-IgA) and CLIA was used to detect a novel EBV-related biomarker (P85-Ab) and two antibodies of VCA (IgM and IgG) to establish a risk prediction model for NPC. This evidence concerns the gene CD40LG and nasopharyngeal carcinoma.